Image Courtesy – Penn Medicine

PLEASE NOTE THAT THE CONTENT PROVIDED IN THIS WRITE-UP IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED AS A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT.

Boasting a staggering $46 billion in turnover, the diabetes market stands as a colossal and highly profitable industry(Source:- International Diabetes Federation). Despite persistent assurances of miraculous solutions, the quest for effective treatment remains unsatisfied, leaving patients grappling with either excessive medication regimens or the inability to afford essential drugs. This dire circumstance paints a desperate picture, with pharmaceutical companies emerging as the primary beneficiaries.

What’s the current background of the disease?

Diabetes mellitus and diabetic retinopathy (DR) represent substantial global public health challenges. Professor Andrew Boulton, President of the International Diabetes Federation (IDF), recently characterized diabetes as a “pandemic of unprecedented magnitude” coinciding with the release of the latest epidemiologic estimates of the worldwide disease burden. According to the IDF’s most recent report, more than 10.5% of the global adult population, surpassing half a billion individuals, currently grapples with diabetes.

Alarming projections suggest that this figure is poised to escalate significantly, reaching nearly 800 million individuals by 2045. Importantly, the impact of this disease extends universally, affecting countries worldwide irrespective of their income or development status. While diabetes and other “non-communicable diseases” were historically considered primarily prevalent in high-income developed nations, the current reality reveals a shift, with more individuals living with diabetes in the developing world than in established developed countries.

A predominant emphasis on monitoring blood glucose levels in medical practice has resulted in an excessive dependence on medication, often without adequate consideration for potential hazardous side effects. Patients find themselves ensnared in a recurring pattern of treatment, frequently failing to impede the advancement of the disease. Consequently, this cycle can result in severe consequences such as amputations, blindness, and heart attacks.(Source – DW)

What’s the market size like?

The following data has been taken from a recent report titled “The Global Diabetes Therapeutics and Diagnostics Market Report ” done by Precision Reports. The complete report can be purchased via the following link. (Link 01)

The projected size of the global Diabetes Therapeutics and Diagnostics market is anticipated to reach USD 143,500 million by 2031, up from USD 117,140 million in 2021, reflecting a CAGR(Compound annual growth rate) of 2.5% during the period 2022-2031. In light of the economic shifts induced by the health crisis, Insulin, accounting for % of the global market in 2021, is expected to be valued at USD million by 2031, experiencing a revised % CAGR in the post-COVID-19 era. The Type 1 Diabetes segment is forecasted to undergo an % CAGR throughout the entire projection period.

As of 2021, the China Diabetes Therapeutics and Diagnostics market size stand at USD million, while North America and Europe are valued at USD million and USD million, respectively. The North America market represents % in 2021, with China and Europe accounting for % and %, respectively. Projections suggest that China’s share will reach % in 2031, with a trailing CAGR of % during the analysis period. Noteworthy Asian markets include Japan, South Korea, and Southeast Asia, with CAGR %, %, and %, respectively, over the next six years. In the European Diabetes Therapeutics and Diagnostics landscape, Germany is anticipated to reach USD million by 2031, with a CAGR of % throughout the forecast period.

With a commitment to industry-standard accuracy in analysis and maintaining high data integrity, the report endeavors to uncover key opportunities within the global Diabetes Therapeutics and Diagnostics market, assisting players in establishing a robust market position. Buyers of the report gain access to verified and reliable market forecasts, including projections for the overall size of the global Diabetes Therapeutics and Diagnostics market in terms of revenue.

How diabetes affects the Global South

Recent estimates indicate that a staggering 415 million people worldwide grapple with diabetes, approximately translating to one in eleven of the global adult population. Alarmingly, it is suggested that 46% of these individuals with diabetes remain undiagnosed, and projections foresee a surge to 642 million people affected by diabetes globally by 2040.

Contrary to historical perceptions, diabetes is not confined to affluent Western nations; rather, its prevalence is two to three times higher in low- and lower-middle-income countries, with this alarming trend on a rapid incline.

Various factors contribute to the escalating prevalence of diabetes in lower-income countries. Age and obesity exhibit correlations akin to those in high-income nations, and the surge in these countries is exacerbated by significant lifestyle shifts. The swift transition from rural to urban living, driven by rapid industrialization, often results in a shift from manual labor to sedentary, office-based occupations. Additionally, dietary habits undergo a transformation from natural, plant-based diets to pre-packaged, high-calorie, high-sugar foods—establishing critical risk factors for diabetes development.

Genetics also intertwines with lifestyle risk factors, particularly in South Asians, where various polymorphisms have been identified, amplifying the predisposition to diabetes-related risk factors. This combined genetic and lifestyle influence has been calculated to potentially result in a sixfold increase in diabetes risk among this population.

The populations most vulnerable to diabetes are coincidentally among the fastest-growing globally. There is an urgent need for a sustainable system in these countries, recognizing that in some regions, up to one in five adults may be living with diabetes. This issue transcends individual health concerns, transforming into a societal challenge that demands public health policies mindful of its collective impact.

Link 01 – https://www.precisionreports.co/purchase/20247509